NVAX vs PFE: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
NVAX (Novavax) and PFE (Pfizer) share investment themes but are different businesses. The right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme.
NVAX vs PFE: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | NVAX | PFE | What it tells you |
|---|---|---|---|
| Forward P/E | -13.49 | 8.85 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 2.43 | 0.31 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 19% of range | 30% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Before you buy: how NVAX and PFE affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NVAX and PFE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NVAX and PFE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Novavax (NVAX) do?
Novavax is a biotechnology company known for protein-based vaccines and its proprietary Matrix-M adjuvant, a saponin-based compound that boosts the immune response to a vaccine. Its best-known product is Nuvaxovid, a protein-based COVID-19 vaccine that offered an alternative to the mRNA shots from Pfizer and Moderna. After years of manufacturing and cash-burn struggles, Novavax restructured its strategy: rather than carrying the full cost of producing and marketing vaccines itself, it now leans on partners to commercialize its products and licenses its adjuvant technology to others.
What does Pfizer (PFE) do?
Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. Its portfolio spans oncology (a strategic priority, expanded sharply by the acquisition of cancer drugmaker Seagen), vaccines (including pneumococcal franchise Prevnar and its COVID-19 vaccine Comirnaty, partnered with BioNTech), internal medicine and cardiology (such as the Vyndaqel/Vyndamax family and Eliquis, co-marketed with Bristol Myers Squibb), immunology and inflammation, and antivirals (including the COVID treatment Paxlovid). Pfizer makes money selling these drugs to wholesalers, pharmacies, hospitals, and governments worldwide. The company saw an enormous revenue surge from COVID-19 products during the pandemic, then a steep decline as that demand normalized, leaving it to refill growth through its pipeline, oncology expansion, and acquisitions while a wave of patent expirations looms later this decade. Founded in 1849 and headquartered in New York City, Pfizer is a mature, dividend-paying large-cap navigating a post-COVID reset.
NVAX vs PFE: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- NVAX drivers: Sanofi partnership and milestones; Matrix-M adjuvant licensing.
- PFE drivers: Oncology expansion via Seagen; Broad, diversified portfolio.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Novavax remains a speculative small-cap biotech with meaningful risks. For PFE, pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap.
NVAX or PFE: which should you pick?
NVAX vs PFE: the full fundamentals
NVAX. These figures are approximate and tied to the asOf date; verify live numbers before acting. Novavax's revenue is increasingly lumpy because it depends on one-time milestone and licensing payments that may not repeat quarter to quarter, so a single strong quarter can overstate the run-rate. Traditional earnings multiples are of limited use for a transitioning biotech like this, where the value depends on future partner milestones and royalties rather than steady product sales.
PFE. Pfizer trades at a below-market multiple and a high dividend yield, reflecting investor concern about the post-COVID revenue reset and a looming patent cliff. Its valuation balances substantial cash generation and diversification against questions over whether the pipeline and Seagen-led oncology push can restore durable growth.
Headline figures (approximate, Jul 2026): NVAX shows revenue (2026 guidance) ~$230 million to $270 million range guided for full-year 2026, q1 2026 revenue ~$140 million, above expectations, driven largely by partnership and licensing income, revenue mix Weighted toward licensing, royalties, and milestones rather than direct product sales, market cap Small-cap (roughly a low single-digit billion; verify live); PFE shows revenue (ttm) ~$60 billion, operating margin ~25%, recovering post-COVID normalization, net income (ttm) multi-billion, variable with COVID product swings, dividend yield ~6%, high for large-cap pharma.
The bottom line: NVAX vs PFE
NVAX and PFE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined NVAX and PFE exposure against your real portfolio. It is not an investment adviser.
Wondering how NVAX or PFE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Novavax with AI
Connect the broker you already use and ask Walnut's AI how NVAX fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between NVAX and PFE?
+
Novavax is a biotechnology company known for protein-based vaccines and its proprietary Matrix-M adjuvant, a saponin-based compound that boosts the immune response to a vaccine. Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is NVAX or PFE the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, NVAX or PFE?
+
On forward P/E (as of August 2026), NVAX trades at -13.49x and PFE at 8.85x, so NVAX is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both NVAX and PFE?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of NVAX vs PFE?
+
NVAX: Novavax remains a speculative small-cap biotech with meaningful risks. Its revenue increasingly depends on partners such as Sanofi and Pfizer, so milestone timing, partner decisions, and program prioritization are largely outside its control. Demand for COVID vaccines has fallen sharply from pandemic peaks, and seasonal booster uptake is uncertain, which pressures the underlying Nuvaxovid franchise. The company has a history of cash burn, dilution, manufacturing setbacks, and volatile results, and its stock can swing sharply on trial data, regulatory news, and deal announcements. Guidance ranges are wide and depend on licensing income that may not recur. Competition in vaccines and adjuvants is intense, and there is no guarantee that new Matrix-M partnerships will materialize on favorable terms. PFE: Pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap. COVID-19 product revenue (Comirnaty, Paxlovid) has fallen sharply and remains volatile and hard to forecast. The Seagen deal added substantial debt, and large acquisitions carry integration and return risk. Drug pricing pressure, including US policy such as Medicare negotiation, threatens margins on key products. Pipeline setbacks, clinical-trial failures, and regulatory decisions can swing the stock, and the company must continually prove it can generate new blockbusters to sustain growth as legacy drugs mature.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell NVAX or PFE; figures are approximate and dated (as of August 2026). Verify current data before investing.